Antibody Information
General Information of This Antibody
| Antibody ID | ANI0DAWXS |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti human BCMA IgG1 antibody |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
AMG-224 [Phase 1]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Objective Response Rate (ORR) |
23.00% (heavily pretreated population of patients with R/R MM with a median of seven lines of prior therapy)
60.00% (in a phase 1 trial of GSK2857916) |
|||
| Patients Enrolled |
Relapsed or refractory (R/R) multiple myeloma (MM).
|
||||
| Administration Dosage |
Every 3 weeks (Q3W) at prespecified doses of 30-300 mg in a 3+3 design.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma.
|
||||
| Primary Endpoint |
AmG 224 was generally well tolerated up to 190 mg Q3W.
|
||||
| Other Endpoint |
ORR=23.00% (95% CI,11.00-39.00%), including six responses in dose escalation and three responses in the dose expansion. Two (5.00%) patients were CR and 7 (18.00%) patients were PR.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT02561962 | Clinical Status | Phase 1 | ||
| Clinical Description |
A phase 1 first in human study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of AMG 224 in subjects with relapsed or refractory multiple myeloma.
|
||||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.